Monte Rosa Therapeutics (GLUE) vs Vor Biopharma (VOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Monte Rosa Therapeutics (GLUE) has outperformed Vor Biopharma (VOR) over the past year, gaining 37.8% versus a loss of 44.4%. Over five years, GLUE leads with a -52.0% price change compared with -93.9% for VOR. Vor Biopharma is the larger company by market cap ($1.11 billion vs $867.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLUE | VOR |
|---|---|---|
| Share price | $10.17 | $18.78 |
| Market cap | $867.64M | $1.11B |
| 1-day change | +3.04% | +2.57% |
| YTD return | -35.14% | +43.58% |
| 1-year return | +37.80% | -44.44% |
| 5-year return | -52.03% | -93.93% |
| P/E ratio (TTM) | — | 0.10 |
| EPS (TTM) | $-1.75 | $184.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.77 | $33.50 |
| 52-week low | $7.65 | $6.50 |
| Distance from 52-week high | -60.54% | -43.94% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +175.32% | +107.67% |
| Average volume | 1.30M | 999.37K |
| Shares outstanding | 85.31M | 59.16M |
| Employees | 173 | 76 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLUE has outperformed VOR by 82.2 percentage points over the past year.
About Monte Rosa Therapeutics
GLUE stock →Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
Healthcare · Biotechnology · 173 employees
About Vor Biopharma
VOR stock →Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
Healthcare · Biotechnology · 76 employees
GLUE vs VOR FAQ
Which is bigger, Monte Rosa Therapeutics or Vor Biopharma?
Vor Biopharma (VOR) is larger, with a market capitalization of $1.11B compared with $867.64M for Monte Rosa Therapeutics (GLUE).
Which stock has performed better over the past year, GLUE or VOR?
GLUE returned +37.80% over the past 12 months, compared with -44.44% for VOR (price return, excluding dividends). Past performance does not predict future results.
Are Monte Rosa Therapeutics and Vor Biopharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.